spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Almirall partners with the Chemical Institute of Sarriŕ (IQS) to bring pharmacy students’ training closer to real industry

Almirall

The agreement will allow those studying the bachelor’s degree in Pharmacy in IQS-URL to get training in actual pharmaceutical manufacturing facilities for the first time


 

From left to right: Dr. Giorgia Miotto (General Director, Blanquerna), Dr. Karl Ziegelbauer (Chief Scientific Officer, Almirall), Dr. Salvador Borrós Gómez (General Director, IQS), Sonia Amorós Ramos (Director of Administration, IQS)

Barcelona (Spain), October 13, 2022Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, and the Chemical Institute of Sarria (IQS), educational institution, founding member of the Ramon Llull University (URL) of Barcelona, have announced a collaboration agreement that will allow students in the third year of the Bachelor’s degree in Pharmacy URL (IQS – Blanquerna) to carry out for the first time an internship in industrial facilities which meet the real requirements of the industry. The internships will begin in the second term of the 22-23 academic year.

"We are excited to be pioneers in collaborating with institutions such as IQS, a benchmark in science education, and to offer students the opportunity to experience the actual manufacturing process of a drug, which involves a series of procedures and regulations that are difficult to find in the academic environment", said Dr. Karl Ziegelbauer, Chief Scientific Officer of Almirall, who added: "This agreement stems from our desire to open our doors to innovation and share our knowledge of the pharmaceutical industry".

For his part, Dr. Salvador Borrós, general director of IQS, said: "the practical dimension has always been one of the characteristics of IQS's teaching methodology and this agreement reinforces the institution's commitment to training in which innovation and the close relationship between IQS and companies are very present".

The collaboration establishes the use by students of Pharmacy URL (IQS-Blanquerna) of Almirall's facilities and technologies in its manufacturing area in St. Feliu de Llobregat (Barcelona). The students, who will be completing the internship as a complement to the Pharmaceutical Technology subject, will learn aspects such as the impact on the pharmaceutical form, the different production equipment, the production process, and batch size, among others. In addition, they will also receive training on manufacturing regulations in production environments, which is essential for accessing Almirall's facilities and complying with the Good Manufacturing Practices (GMP) certification.

Almirall's Sant Feliu de Llobregat (Barcelona) centre, inaugurated in 2006, is the company's R&D centre of reference and currently has 7,400 square metres of fully equipped laboratories and production area. This agreement is the first example of the willing of Almirall to offer its facilities to other scientists, biotech and academic institutions and to foster an ecosystem of cutting-edge innovation.
phone + 34 932 913 000
email corporate.communication@almirall.com
web https://www.almirall.com/
 
Print this page
Send to a friend
   
spacer
News and Press Releases

CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth

 PE overhang to fuel CDMO valuations and expansions, while VC overhang will fuel continued demand for services in spite of adverse global conditions
More info >>


White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement